Short-term therapeutic effect of Endostar combined with chemotherapy for advanced colorectal cancer:a meta-analysis
- VernacularTitle:恩度联合化疗治疗晚期结直肠癌的近期疗效的meta分析
- Author:
Yongqin PAN
1
;
Genlong JIAO
Author Information
1. 暨南大学附属第一医院普外科//暨南大学附属第一医院骨二科
- Keywords:
Endostar;
advanced colorectal cancer;
meta-analysis;
randomized controlled trials
- From:
Journal of Southern Medical University
2014;(2):270-274
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the safety and efficacy of Endostar combined with chemotherapy in the treatment of end-stage colorectal cancer. Methods The relevant randomized controlled trials were retrieved from the electronic databases of Cochrane library, PubMed, EMbase, CNKI, CBM, VIP and Chinese Medical Association. The retrieval time limit was from the database construction to January 2013. The data were extracted from eligible studies assessed for methodological quality according to Cochrane handbook for systematic reviews and analyzed using RevMan 5.2 software. Results Five randomized controlled trials involving 220 cases were included for meta-analysis. The results showed that Endostar combined with chemotherapy had an overall advantage over chemotherapy alone in terms of complete response rate (10.91%vs 2.73%RR=4.08, 95%CI:1.19-13.95, P=0.02), partial response rate (48.18% vs 30.91% RR=2.18, 95% CI: 1.23-3.87, P=0.007), progressive disease (15.45% vs 41.82% RR=0.25, 95% CI: 0.13-0.47, P<0.0001), and the response rate (60.00% vs 33.64% RR=3.23, 95% CI: 1.79-5.81, P<0.0001). Clinical benefit response(82.73%vs 55.45%RR=4.30,95%CI:1.19-13.95, P<0.0001). The main adverse reactions included nausea, vomiting, constipation, palpitation, and electrocardiogram changes. Conclusion Endostar combined with chemotherapy is effective for advanced colorectal cancer and can be used as a routine treatment.
